[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f181TkomntASJMqqcEC0eHJWWIQp-eBYJcLXuK3X5yA4":8,"$fd7cQHm_Tya3EBr0mvqauULrXx0TAI8BEaekOl9FVb6E":55,"$f3nXv3iCeTauw6PMBVQ604eTU5bO1BqSSYBdOvtM825k":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},57251,869163,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//LSapFNe3WLeWiibllvbkcs4g9YhSGQbm.png","王辉坡","石家庄市藁城人民医院","甲状腺乳腺外科","主治医师",10,0,"曲妥珠单抗用药安全指南：乳腺癌Ⅱ期靶向治疗中的关键细节","","https://ystcdn.venuertc.com/venue/AI/a4662936-bd0f-4f35-98c9-c63dde98e71a.jpg","\u003Cdiv class=\"material-guide\">\n\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">曲妥珠单抗用药安全指南：乳腺癌Ⅱ期靶向治疗中的关键细节\u003C/h2>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #eef6fb 0%, #f3f9f6 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、曲妥珠单抗简介及作用原理 🧬\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>提到靶向治疗药物，曲妥珠单抗（Trastuzumab）是近年最受关注的一个。它是一种单克隆抗体药物，主要以静脉注射剂型应用。曲妥珠单抗的作用机制是结合并阻断一种名为HER2的蛋白，这种蛋白在部分细胞表面大量存在。通过这一机制，曲妥珠单抗能够抑制异常细胞生长并诱导细胞凋亡，从而为治疗提供帮助。\u003C/p>\n      \u003Cp>曲妥珠单抗不含激素，不抑制机体全部免疫系统，仅针对特定细胞表面受体发挥作用。该药通常以单独用药或与其他治疗联合，每次给药前需稀释，严格按照医嘱配制。\u003C/p>\n      \u003Cp>\u003Cstrong>关键数据：\u003C/strong> 临床资料表明，曲妥珠单抗有关联合方案的总有效率可达60%~70%（参考：Baselga et al., 1998）。\u003C/p>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong> 选择曲妥珠单抗，务必确认是否有HER2过度表达，并在专业医疗机构下接受给药。\u003C/p>\n      \u003Cp class=\"quote-style\">引用文献：Baselga, J., Tripathy, D., Mendelsohn, J., et al. (1998). \"Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.\" Seminars in Oncology, 25(5 Suppl 11), 3-8.\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f8f5ee 0%, #fcf7f6 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、剂型规格与正确给药方式💉\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗目前主要以粉针剂（需要配制成静脉注射液）和皮下注射制剂两类。每瓶含量多为150mg或420mg，需在静脉注射时根据体重和疗程调整剂量。无论哪一种剂型，都不能自行注射，均需在医院专业人员操作。\u003C/p>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong>\u003C/p>\n      \u003Cul>\n        \u003Cli>严格按体重计算首次负荷剂量及随后维持剂量。\u003C/li>\n        \u003Cli>初次给药应缓慢滴注60至90分钟，随后维持剂量可在30分钟滴完。\u003C/li>\n        \u003Cli>用专用输液管和装置，避免与他药直接混合。\u003C/li>\n        \u003Cli>如出现注射部位反应（红肿、肿胀、疼痛），需及时报告医护人员。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"important-tip\">特别提醒：粉针剂需按说明书用无菌注射用水稀释并立即使用，调配后最长保存期一般不超过24小时。\u003C/p>\n      \u003Cp>有患者在日常护理中出现输液部位不适，经调整注射速度和换部位后症状缓解。这提醒我们静脉通道选择及注射操作规范非常重要。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f2f6ef 0%, #eefdff 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、服药流程及疗程管理 📅\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗采用长期周期用药方式。标准流程为：\u003C/p>\n      \u003Cul>\n        \u003Cli>初次使用负荷剂量，一般为每千克体重8mg，然后每周或每三周维持剂量（每千克体重6mg）。\u003C/li>\n        \u003Cli>维持剂量按计划定期给予，治疗期间建议每次注射前进行体重复测。\u003C/li>\n        \u003Cli>疗程中若有中断，需重新评估从负荷剂量开始，还是继续原有维持剂量。\u003C/li>\n        \u003Cli>多数方案推荐直至完成规定周期或出现需要中止的特殊情况。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\u003Cstrong>实际案例：\u003C/strong>有一位中年女性患者接受靶向治疗，按照曲妥珠单抗标准剂量联合辅助输液，期间出现局部不适。根据护理规定及时调整，确保继续顺利完成疗程。\u003C/p>\n      \u003Cp class=\"important-tip\">需要注意：疗程内少一针或中断用药，可能影响疗效，不能自行停药或延迟。\u003C/p>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong> 每次输液前与医生沟通近期身体状况，有任何身体变化及早反馈。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f6f8fa 0%, #eef5ff 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、不良反应与处理方法 🚨\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗虽有靶向性，但仍然存在一定的不良反应风险。常见副作用包括：\u003C/p>\n      \u003Cul>\n        \u003Cli>输注相关反应（发热、寒战、皮肤潮红）\u003C/li>\n        \u003Cli>注射部位不适（红肿、刺痛）\u003C/li>\n        \u003Cli>皮肤轻微过敏\u003C/li>\n        \u003Cli>心脏功能影响\u003C/li>\n        \u003Cli>罕见呼吸系统症状\u003C/li>\n      \u003C/ul>\n      \u003Cp>根据“大型对照研究”，约15%患者出现不同程度的输注相关反应，严重反应发生率低于2%（Piccart-Gebhart et al., 2005）。\u003C/p>\n      \u003Cp>\u003Cstrong>处理建议：\u003C/strong>\u003C/p>\n      \u003Cul>\n        \u003Cli>首次给药期间需严密观察，出现发热、寒战可以暂停给药并采取对症处理。\u003C/li>\n        \u003Cli>如有注射部位不适，可通过减慢滴速或更换静脉通道改善。\u003C/li>\n        \u003Cli>发现心脏异常应立即告知医务人员，必要时暂停用药。\u003C/li>\n      \u003C/ul>\n      \u003Cp>规律复查心脏功能指标（如超声心动图）可帮助识别早期异常。\u003C/p>\n      \u003Cp class=\"quote-style\">引用文献：Piccart-Gebhart, M. J., et al. (2005). \"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\" N Engl J Med, 353(16): 1659-1672.\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f7faf3 0%, #f6f6fd 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、药物相互作用与并用规则 ⚠️\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗使用期间，合理避免药物相互作用同样重要。\u003C/p>\n      \u003Cul>\n        \u003Cli>不宜与蒽环类药物（如多柔比星）同时应用，有加重心脏毒性的风险。\u003C/li>\n        \u003Cli>与其他抗肿瘤药物联合时需遵循权威指南和医嘱，避免自行叠加疗法。\u003C/li>\n        \u003Cli>目前暂无与常见降压、降糖药的显著药物相互作用，但应主动告知所有合用药品。\u003C/li>\n      \u003C/ul>\n      \u003Cp>本药对肝脏代谢相对影响较小，血药浓度稳定。合用期间如需使用消炎痛、抗生素等，请由医生评估是否调整用药顺序。\u003C/p>\n      \u003Cp class=\"important-tip\">正确做法：随访期间主动告知医生当前所有药品和保健品清单，避免自行添加新药。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f9f6f8 0%, #f7fbfa 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、特殊人群用药细节 👩‍👧‍👦\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗的安全性数据表明，部分人群使用时需格外谨慎：\u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>老年人：\u003C/strong>需监测心脏功能，适当调整给药速度。\u003C/li>\n        \u003Cli>\u003Cstrong>肝、肾功能异常者：\u003C/strong>轻中度一般无需调整剂量，但严重损害者建议酌情评估用药必要性。\u003C/li>\n        \u003Cli>\u003Cstrong>孕妇及哺乳期妇女：\u003C/strong>动物实验发现有胎儿毒性风险，孕期禁用，哺乳期也应暂停哺乳。\u003C/li>\n        \u003Cli>\u003Cstrong>儿童：\u003C/strong>安全性与有效性尚未确立，暂不推荐。\u003C/li>\n      \u003C/ul>\n      \u003Cp class=\"important-tip\">需要注意：孕期、哺乳期用药前必须排除禁忌，接受专业评估。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #fbf9f7 0%, #f8fafb 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、储存方法与药品管理 📦\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗需冷藏储存，主要注意以下几点：\u003C/p>\n      \u003Cul>\n        \u003Cli>\u003Cstrong>未开瓶：\u003C/strong>应存于2℃~8℃环境下，切忌冷冻。\u003C/li>\n        \u003Cli>\u003Cstrong>已配制溶液：\u003C/strong>建议24小时内用完，期间也要冷藏保存。\u003C/li>\n        \u003Cli>不得与食物等其他物品一同放置，保持药品干燥、避光。\u003C/li>\n        \u003Cli>药品超过有效期严禁使用，及时回收处理。\u003C/li>\n      \u003C/ul>\n      \u003Cp>有患者家属误将药品放入冷冻室，导致药效降低。药品说明书明确禁止冷冻，此类错误需避免。\u003C/p>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong> 家庭非专业环境下不建议自存药品，确保每瓶药品在医疗设施内配制用完。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section\" style=\"background: linear-gradient(90deg, #f7faf8 0%, #faf7fc 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、漏服/过量处理办法⏱️\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗为医院常规注射管理，个人不会出现自行漏服或过量。但如在医院疗程安排中出现漏用或超量风险，需采取下列步骤：\u003C/p>\n      \u003Cul>\n        \u003Cli>漏服应尽快与主治医生沟通，不可自行延后或补加剂量。\u003C/li>\n        \u003Cli>如误用过量，将加重部分不良反应风险，需立即中止并联系医生做专项监护和处理。\u003C/li>\n        \u003Cli>切忌偷偷补用或随意调整下次剂量。\u003C/li>\n      \u003C/ul>\n      \u003Cp>\u003Cstrong>正确做法：\u003C/strong>一切用药变动需要由主治医生统筹决策。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section material-section-summary\" style=\"background: linear-gradient(90deg, #f6f8fd 0%, #f7faf6 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与用药提醒🔔\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cp>曲妥珠单抗作为现代靶向治疗重要一环，对提升治疗效果起到了重要作用，但只有在专业指导下规范操作，才能最大限度提高用药安全性和疗效。\u003C/p>\n      \u003Cp>\u003Cstrong>最重要的两点：\u003C/strong>\u003C/p>\n      \u003Cul>\n        \u003Cli>严禁自行调整注射剂量和疗程。\u003C/li>\n        \u003Cli>留意心脏、输注相关不适，及时与医生沟通。\u003C/li>\n      \u003C/ul>\n      \u003Cp>安全用药、规范管理，是保障效果与健康的基石。遇到任何疑问，马上咨询专业医生或药师是最稳妥的选择。\u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003Cdiv class=\"material-section material-section-reference\" style=\"background: linear-gradient(90deg, #eaf6fa 0%, #f9f9f9 100%);\">\n    \u003Ch2 class=\"material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献📖\u003C/h2>\n    \u003Cdiv class=\"material-content\">\n      \u003Cul class=\"material-references\">\n        \u003Cli>Baselga, J., Tripathy, D., Mendelsohn, J., et al. (1998). \"Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.\" \u003Ci>Seminars in Oncology\u003C/i>, 25(5 Suppl 11), 3-8.\u003C/li>\n        \u003Cli>Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., et al. (2005). \"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\" \u003Ci>N Engl J Med\u003C/i>, 353(16): 1659-1672.\u003C/li>\n        \u003Cli>Swain, S. M., Baselga, J., Kim, S. B., et al. (2015). \"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.\" \u003Ci>N Engl J Med\u003C/i>, 372(8): 724-734.\u003C/li>\n        \u003Cli>National Comprehensive Cancer Network. (2023). \u003Ci>NCCN Clinical Practice Guidelines in Oncology: Breast Cancer\u003C/i>, Version 4.2023.\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/div>\n\n\u003C/div>\n\n\u003Cstyle>\n/* 独立样式命名，防止与外部页面冲突 */\n.material-guide {\n  font-family: \"Helvetica Neue\", Helvetica, Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  color: #24313a;\n  line-height: 1.76;\n  max-width: 880px;\n  margin: 40px auto 60px auto;\n  background: #ffffff;\n  padding: 40px 26px 40px 26px;\n  border-radius: 20px;\n  box-shadow: 0 4px 24px rgba(100, 128, 200, 0.09), 0 1.5px 10px rgba(70, 92, 128, 0.09);\n}\n.material-title {\n  font-size: 2.05em;\n  line-height: 1.25;\n  text-align: left;\n  margin-bottom: 46px;\n  color: #12486b;\n  font-weight: 800;\n  letter-spacing: .05em;\n  border-left: 7px solid #52bead;\n  padding-left: 18px;\n}\n.material-section {\n  margin-bottom: 40px;\n  border-radius: 16px;\n  padding: 29px 26px 24px 26px;\n  background-size: cover;\n  background-position: center;\n  box-sizing: border-box;\n}\n.material-subtitle {\n  font-size: 1.37em;\n  color: #3e5675;\n  font-weight: 700;\n  padding-bottom: 10px;\n  padding-top: 4px;\n  display: flex;\n  align-items: center;\n  gap: 0.32em;\n  margin-bottom: 22px;\n  border-left: 5px solid #b8e7da;\n  padding-left: 13px;\n  background: rgba(255,255,255,0.74);\n  border-radius: 7px;\n}\n.material-content {\n  font-size: 1.01em;\n  color: #294157;\n}\n.material-content ul {\n  padding-left: 2.2em;\n  margin-top: 0.5em;\n  margin-bottom: 1em;\n}\n.material-content li {\n  margin-bottom: 4px;\n}\n.material-content .important-tip {\n  display: block;\n  background: #f6fafd;\n  border-left: 5px solid #52bead;\n  padding: 9px 14px;\n  margin: 16px 0 13px 0;\n  border-radius: 7px;\n  color: #1d574b;\n  font-size: 1em;\n  font-weight: 500;\n}\n.material-content .quote-style {\n  background: #f4f7ff;\n  border-left: 3px solid #7dbaf1;\n  margin: 10px 0 18px 0;\n  padding: 8px 13px;\n  font-size: 0.99em;\n  color: #23627a;\n  border-radius: 6px;\n  font-style: italic;\n}\n.material-section-summary {\n  border: 1.5px solid #aad5fc;\n  box-shadow: 0 2px 12px rgba(120,150,200,0.05);\n}\n.material-section-reference {\n  margin-bottom: 0;\n  margin-top: 40px;\n  border: 1.2px solid #b7e3d8;\n  background: linear-gradient(89deg, #eaf6fa 0%, #f9f9f9 100%);\n}\n.material-references {\n  font-size: 0.98em;\n  color: #22415d;\n  line-height: 1.72;\n  margin: 0;\n  padding-left: 1.8em;\n}\n.material-references li {\n  margin-bottom: 8px;\n}\n@media (max-width: 700px) {\n  .material-guide {\n      padding: 6vw 2vw 8vw 2vw;\n      max-width: 98vw;\n      font-size: 1em;\n  }\n  .material-title {\n      font-size: 1.21em;\n      padding-left: 8px;\n  }\n  .material-section, .material-content {\n      padding: 2vw 2vw 3vw 2vw;\n      font-size: 0.99em;\n  }\n  .material-subtitle {\n      font-size: 1.14em;\n      padding-left: 7px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"material-guide\">\n\n  \u003Ch2 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44,",517,"2025-08-08 15:41:40","曲妥珠单抗, 乳腺癌, 靶向治疗, 不良反应, 用药指南","了解曲妥珠单抗的给药方式和注意事项，提升乳腺癌靶向治疗的用药安全性和疗效，特别关注心脏健康，确保规范用药。","2025-08-09 17:16:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":20,"result":57,"totalSize":21},[],{"code":9,"msg":10,"message":6,"data":59,"success":54},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]